Pneumococcal disease: prospects for a new generation of vaccines.
about
Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and pneumonia with consolidation on x-ray in children under two years of ageStructure of the catalytic domain ofStreptococcus pneumoniaesialidase NanASynthetic 6B di-, tri-, and tetrasaccharide-protein conjugates contain pneumococcal type 6A and 6B common and 6B-specific epitopes that elicit protective antibodies in miceCombinatorial library cloning of human antibodies to Streptococcus pneumoniae capsular polysaccharides: variable region primary structures and evidence for somatic mutation of Fab fragments specific for capsular serotypes 6B, 14, and 23FGlycolytic enzymes associated with the cell surface of Streptococcus pneumoniae are antigenic in humans and elicit protective immune responses in the mouse.Invasiveness of serotypes and clones of Streptococcus pneumoniae among children in FinlandDepletion of complement has distinct effects on the primary and secondary antibody responses to a conjugate of pneumococcal serotype 14 capsular polysaccharide and a T-cell-dependent protein carrier.Vaccine technology: looking to the future.Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants.A live recombinant avirulent oral Salmonella vaccine expressing pneumococcal surface protein A induces protective responses against Streptococcus pneumoniaeAntibiotic resistant Streptococcus pneumoniae.Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharidesProtective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae.Pneumococcal diversity: considerations for new vaccine strategies with emphasis on pneumococcal surface protein A (PspA).Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic.Chromogenic assay measuring opsonophagocytic killing capacities of antipneumococcal antiseraRegulatory T cells in the antibody response to Haemophilus influenzae type b polysaccharideRepertoire of human antibodies against the polysaccharide capsule of Streptococcus pneumoniae serotype 6B.Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections.Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections.Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines.Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccineAvidity, potency, and cross-reactivity of monoclonal antibodies to pneumococcal capsular polysaccharide serotype 6BIdentification and characterization of a novel family of pneumococcal proteins that are protective against sepsis.Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide.Pneumococcal conjugate vaccines overcome splenic dependency of antibody response to pneumococcal polysaccharidesA multi-laboratory evaluation of an enzyme-linked immunoassay quantitating human antibodies to Streptococcus pneumoniae polysaccharides.Immunization with recombinant Streptococcus pneumoniae neuraminidase NanA protects chinchillas against nasopharyngeal colonization.Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin a encapsulated in microspheres.Role of HtrA in the virulence and competence of Streptococcus pneumoniaeRethinking recommendations for use of pneumococcal vaccines in adults.Haemophilus influenzae type b conjugate vaccines.Development of a model of low-inoculum Streptococcus pneumoniae intrapulmonary infection in infant rats.Immunization with native or recombinant Streptococcus pneumoniae neuraminidase affords protection in the chinchilla otitis media modelPurification and seroreactivity of pneumococcal surface adhesin A (PsaA).Characterization of specific immunoglobulin G (IgG) and its subclasses (IgG1 and IgG2) against the 23-valent pneumococcal vaccine in a healthy adult population: proposal for response criteria.Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells.Meningococcal group C conjugate vaccines.Cancer vaccines and carbohydrate epitopes.Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults.
P2860
Q24245934-AAAE8872-4A6C-4CAA-8501-CA5472C9D541Q27651923-5C43685E-B104-408D-9949-98D9663C5250Q28346515-87E33CA0-7953-4E7F-8506-FC793A71E196Q30658618-E989F0B2-A31A-4785-BECE-28A44B260F17Q33208122-08295469-D955-40FF-A832-F8B48E69D4F9Q33558483-3313C9BE-66B6-4488-B889-E79256EEA822Q33558995-F5F9A237-B58A-4CE0-B41A-D138655B0376Q33603392-1D947F5B-60A5-4A4E-80A4-7779224DDEFDQ33753799-5F43A2D2-3E27-42D2-8C09-44C8AD36AA0BQ33757861-D979A8B1-994B-4545-A503-D02AD6F16A03Q33776122-795D1351-252F-4482-BA3F-29DC1C95041AQ33867137-246BE889-73F7-45A6-8C10-F2DBCABEE8D3Q33877194-54989903-0537-4548-BFAF-EDC9513DE85DQ33975380-951B88C5-94FE-4EAE-894E-FEE789E0068CQ33997738-25F3F2C5-1704-4F0B-907B-A1363840DBB5Q33999092-05BC636E-B130-4AA8-9B92-9CCCA2C8E130Q34000337-56AF3D05-059A-4F39-A0CC-83C8A1EEC421Q34000570-1498CC11-31BE-4C48-93D7-889C33FFC8EAQ34001509-75D354DB-D4D9-426F-AD20-25F43E829EC3Q34002470-2862A378-47B6-4FFE-A1EE-E885CD9CB08CQ34002718-781AC765-DC40-4AE2-A8B0-3E06FA9E270EQ34003584-C53681D1-CAA1-4194-A6E1-C3C21F83B4DAQ34005631-9F6AEE64-342A-44FA-A8F4-C835DF8FAFF8Q34005995-EB51D027-FCFA-41D9-A27F-0E3316C917E7Q34007255-B5B9E7BC-447C-4818-85A0-F4EA8D9052B4Q34009763-F77942F9-2A03-4AD2-8197-B50625E3D5A1Q34092415-E91C2C84-5447-43D5-8FA5-26F4F0D32BD6Q34111722-EC34D565-1364-4FC9-85E2-10DA14EB6A9DQ34120517-9B88331D-C3AA-4FC1-8952-66ABD192EFB1Q34144821-0ECD26FB-F926-4B65-9E32-8988833B8A5FQ34326459-FB8CC2E3-FAE2-4B16-B273-E6578AD20415Q34349892-0F3126E3-DCE5-4105-BEF4-BECF7C6F1B5FQ34444527-646907D4-4D0B-491B-814E-4CBD4ADE826DQ34760226-47FB829E-95EF-4BE4-8AEA-1E60341AA454Q35226175-3A4AD785-CEB9-4B99-8D0E-F6EC562D59B2Q35229085-0DC28C9D-7A83-4F67-9C2B-05B59F6320BFQ35229917-CB0F46E2-C657-476E-B4EB-4AE66CBC5A68Q35269816-F98FC1A8-397C-475D-90B5-725F2ED63816Q35525289-0E99B197-D09F-49D4-82EF-929007D0B306Q35533941-F2655A82-36F0-4B76-9969-77EC61D00BD5
P2860
Pneumococcal disease: prospects for a new generation of vaccines.
description
1994 nî lūn-bûn
@nan
1994 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Pneumococcal disease: prospects for a new generation of vaccines.
@ast
Pneumococcal disease: prospects for a new generation of vaccines.
@en
Pneumococcal disease: prospects for a new generation of vaccines.
@nl
type
label
Pneumococcal disease: prospects for a new generation of vaccines.
@ast
Pneumococcal disease: prospects for a new generation of vaccines.
@en
Pneumococcal disease: prospects for a new generation of vaccines.
@nl
prefLabel
Pneumococcal disease: prospects for a new generation of vaccines.
@ast
Pneumococcal disease: prospects for a new generation of vaccines.
@en
Pneumococcal disease: prospects for a new generation of vaccines.
@nl
P356
P1433
P1476
Pneumococcal disease: prospects for a new generation of vaccines.
@en
P2093
P304
P356
10.1126/SCIENCE.8073278
P407
P577
1994-09-01T00:00:00Z